PUNE, India, September 5, 2016 /PRNewswire/ --
ReportsnReports.com adds Amyloidosis - Pipeline Review, H2 2016 marketresearch report complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research
Complete amyloidosis pipeline report spread across 152 pages talking about 17 companies and 25+ drug profiles as well as supported with 34 data tables and 16 figures on amyloidosis industry is now available at http://www.reportsnreports.com/reports/674738-amyloidosis-pipeline-review-h2-2016.html .
Companies active and discussed in this 2016 amyloidosis pipeline research include Alnylam Pharmaceuticals, Inc., Amgen Inc., Arcturus Therapeutics, Inc., BELLUS Health Inc, Bsim2, Celgene Corporation, GlaxoSmithKline Plc, Ionis Pharmaceuticals, Inc., Johnson & Johnson, Neurimmune Holding AG, NeuroPhage Pharmaceuticals, Inc., Oncopeptides AB, Pfizer Inc., Prothena Corporation Plc, Regeneron Pharmaceuticals, Inc., SOM Innovation Biotech SL and Takeda Pharmaceutical Company Limited.
Profiles of amyloidosis drugs covered in the report include ALN-ANG, ALN-TTRsc02, Antisense RNAi Oligonucleotides to Inhibit Amyloid Precursor Protein for Amyloidosis, carfilzomib, CLR-01, daratumumab, doxycycline hyclate, EDE-1307, GSK-2315698 + GSK-2398852, GSK-3039294, inotersen sodium, ixazomib citrate, LUNAR-TTR, Melflufen , Monoclonal Antibody for Amyloidosis, Monoclonal Antibody to Inhibit ATTR for Familial Amyloid Polyneuropathy, Monoclonal Antibody to Target CD66b for Blood Cancer and Metabolic Disorders, NEOD-001, NI-301, NPT-005, Oligonucleotides to Inhibit Transthyretin for Amyloidosis, patisiran , pomalidomide , PRX-004, revusiran , Small Molecules for AL Amyloidosis, Small Molecules to Inhibit Transthyretin for Familial Amyloid Polyneuropathy, Small Molecules to Inhibit Transthyretin Related Amyloid Protein for Familial Amyloidotic Cardiomyopathy, Small Molecules to Inhibit Transthyretin Related Amyloid Protein for Familial Amyloidotic Polyneuropathy , tafamidis meglumine and tolcapone .
Order a copy of Amyloidosis - Pipeline Review, H2 2016 market research report at http://www.reportsnreports.com/Purchase.aspx?name=674738 .
Through this report, readers can gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies. Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage in amyloidosis pipeline. Identify and understand important and diverse types of therapeutics under development for Amyloidosis. Identify potential new clients or partners in the target demographic. Develop strategic initiatives by understanding the focus areas of leading companies. Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics. Devise corrective measures for pipeline projects by understanding Amyloidosis pipeline depth and focus of Indication therapeutics. Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from Amyloidosis pipeline.
On a related note, another research titled Amgen Inc. - Product Pipeline Review - 2016 provides comprehensive information on the therapeutics under development by Amgen Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Drug profiles discussed in this Amgen Inc. focused report cover adalimumab biosimilar, blinatumomab, darbepoetin alfa, denosumab, etanercept, etelcalcetide hydrochloride, romiplostim, AMG-334, bevacizumab biosimilar, evolocumab, fulranumab, panitumumab, rituximab biosimilar, romosozumab, trastuzumab biosimilar, trebananib, abrilumab, AMG-319, AMG-337, AMG-557, AMG-714, AMG-899, ganitumab, omecamtiv mecarbil MR, rilotumumab, tezepelumab, AMG-232, talimogene laherparepvec, AMG-172, AMG-208, AMG-211, AMG-224, AMG-228, AMG-282, AMG-301, AMG-330, AMG-357, AMG-581, AMG-592, AMG-595, AMG-780, AMG-811, AMG-820, AMG-876, AMG-900, AMG-XXX, infliximab biosimilar, pasotuxizumab, solitomab, AM-1638, AM-3189, AM-6226, AM-7209, AM-8553, AM-9514, AMG-0696, AMG-161, AMG-1694, AMG-176, AMG-3969, AMG-511, AMG-570, AMG-8718 and AMG-986. Read more at http://www.reportsnreports.com/reports/538033-amgen-inc-product-pipeline-review-2016.html .
Explore more reports on pharmaceuticals market at http://www.reportsnreports.com/market-research/pharmaceuticals/ .
ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.
Contact: Ritesh Tiwari UNIT no 802, Tower no. 7, SEZ Magarpatta city, Hadapsar Pune - 411013 Maharashtra, India. + 1 888 391 5441 firstname.lastname@example.org
Connect With Us on:
G+ / Google Plus: https://plus.google.com/111656568937629536321/posts
Subscribe to our Free Newsletters!
Cachexia refers to severe muscle and fat loss, anorexia and marked weight loss due to an underlying ...
Exotropia or outward eye deviation is a form of squint. Proper evaluation and timely intervention ...
Glaucoma is a group of disorders involving the optic nerve, often associated with a rise in ...View All